Skip to main content
Caplight Logo









NextPoint Therapeutics

NextPoint Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://nextpointtx.com/

Last Round

Early Stage

VC

Jul 30, 2026

Total Funding Raised

$196M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

NextPoint Therapeutics is a biotechnology company developing precision immuno-oncology therapeutics that target the B7-H7/HHLA2 immune checkpoint axis to treat solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyHHLA2monoclonal antibodyimmune checkpointbiotech startupcancer immunotherapyclinical-stage biotechdrug developmentantibody-drug conjugateADCT-cell engagerbiopharmaclinical trialsimmune evasionbiologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NextPoint Therapeutics Comparables

Compare NextPoint Therapeutics with similar companies based on industry and business-model similarity.

NextPoint Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Harbour BioMed
78%
BeOne Medicines
76%
Hummingbird Bioscience
71%

NextPoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCJul 30, 2026
Series B ExtensionFeb 14, 2024
Series BJan 10, 2023
Series AAug 13, 2020

Key People

Founding team and executive leadership

Ivan Cheung

CEO Member Of Board Of Directors

Executive Team

NextPoint Therapeutics Investors

Notable investors and investment history

NextPoint Therapeutics investors
InvestorRounds
MPM CapitalVC Round
Sixty Degree CapitalSeries B Extension, Series B
Binney Street CapitalSeries A, VC Round, Series B Extension, Series B
MPM BioImpactSeries B, Series A, Series B Extension
Catalio Capital ManagementSeries B, Series B Extension
Invus OpportunitiesSeries B Extension, Series B
Arkin Bio CapitalSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 30, 2026

    $34M raised in early stage VC round.

  • Jul 26, 2026

    Monthly visitors grew 92% MoM.

NextPoint Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NextPoint Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NextPoint Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range32
Year Founded2020
Last FundingJul 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?